-
1.发明授权SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME 无效抗精神病药物包含其制备延迟释放和方法微球
公开(公告)号：EP0669128B1
公开(公告)日：2000-01-05
申请号：EP93924827.4
申请日：1993-11-15
发明人： KINO, Shigemi, Yoshitomi Pharmaceutical Ind. Ltd. , OSAJIMA, Tomonori, Yoshitomi Pharmac. Ind. Ltd. , MIZUTA, Hiroaki, Yoshitomi Pharmaceutical Ind. Ltd
IPC分类号： A61K9/16 , A61K31/445
CPC分类号： A61K9/1647 , A61K31/40 , A61K31/445 , A61K31/4515 , A61K31/505 , A61K31/54 , A61K31/55
摘要： A sustained-release microsphere produced by enclosing a hydrophobic antipsychotic such as bromperidol or haloperidol in a base comprising a biocompatible polymer such as polylactic acid or a lactic acid/glycolic acid copolymer. It can exhibit a desired pharmacological effect, where a long-term administration is necessary, by injecting once every 1 to 8 weeks instead of every day. As a result, a remarkable improvement can be expected in the compliance during maintenance therapy. In addition, the use of the biocompatible polymer serves to entirely dispense with surgical operations such as implantation, facilitates hypodermic and intramuscular injection just like the case of suspending injection, and can dispense with the widrawal of the microsphere. Furthermore, the microsphere can be administered with little aversion and pain.
-
2.发明公开SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME 无效抗精神病药物包含其制备延迟释放和方法微球。
公开(公告)号：EP0669128A1
公开(公告)日：1995-08-30
申请号：EP93924827.4
申请日：1993-11-15
发明人： KINO, Shigemi, Yoshitomi Pharmaceutical Ind. Ltd. , OSAJIMA, Tomonori, Yoshitomi Pharmac. Ind. Ltd. , MIZUTA, Hiroaki, Yoshitomi Pharmaceutical Ind. Ltd
IPC分类号： A61K9/16 , A61K31/445
CPC分类号： A61K9/1647 , A61K31/40 , A61K31/445 , A61K31/4515 , A61K31/505 , A61K31/54 , A61K31/55
摘要： A sustained-release microsphere produced by enclosing a hydrophobic antipsychotic such as bromperidol or haloperidol in a base comprising a biocompatible polymer such as polylactic acid or a lactic acid/glycolic acid copolymer. It can exhibit a desired pharmacological effect, where a long-term administration is necessary, by injecting once every 1 to 8 weeks instead of every day. As a result, a remarkable improvement can be expected in the compliance during maintenance therapy. In addition, the use of the biocompatible polymer serves to entirely dispense with surgical operations such as implantation, facilitates hypodermic and intramuscular injection just like the case of suspending injection, and can dispense with the widrawal of the microsphere. Furthermore, the microsphere can be administered with little aversion and pain.
-
搜索结果
2 条记录 (耗时 0.008 秒)
